From alphastox.com on iCo and others.. check out the website for more if you'd like...cheers
" iCo Therapeutics: iCo is one of the most exciting companies we have seen on the junior side. The company has three assets and the lead asset (ICO-007) is currently in the largest Phase II trial of its kind in the US with interim data expected in the near future. Some of the top eye centers in the US alongside the top clinicians are involved in the trial. Their lead asset, ICO-007 is a treatment for diabetes related blindness (Diabetic Macular Edema or DME). The Phase II trial is being sponsored/funded in large by the Juvenile Diabetes Research Foundation (JDRF) - the single largest funder of Diabetes research in the world. iCo’s management is currently working on a regional partnership for European and/or Asian rights which would be a major catalyst in the near term.
iCo had a very good run from $0.65 when we first introduced the story to our subscribers on December 12th, 2012, to a year high $0.89 on January 3rd, 2013. The stock has since pulled back to $0.52 (as of closing on January 29th, 2013) but the fundamentals of the company are still there and we continue to believe in the story. The reason we got involved with iCo is because the company has diversified assets and has enough cash on their balance sheet to take them to the next stage. We don’t feel that iCo is in any danger of not having enough capital. Many institutional funds have approached iCo’s management about a possible financing and they have constantly been turned down. iCo has approximately $1.7 million in the treasury with around $150,000-$200,000/month burn rate. Most investors look at this and feel that iCo will run out of money by June or July but I don’t feel this way. They recently announced a positive clinical update which proved the drug to be safe and most importantly, they mentioned they won’t have to recruit all 208 patients and can stop at 149. The recruitment is all done and this will save iCo approximately $1.6 million to $2.0 million. Not only that, but there have been a fair number of $0.60 warrants that have been exercised (we hope to get the exact number soon). Lastly, iCo’s secondary asset has a partnership with Immune Pharmaceuticals, a private Israeli company that is going public through an RTO on the Nasdaq. iCo owns 6% of Immune. This 6% ownership in Immune is looking like it’s going to be worth between $2.5 million to $5 million once Immune goes public. So, the near term catalyst for iCo is that once these funds realize that iCo is not in need of extra funding and that there won’t be a financing, funds will have no choice but to acquire shares in the open market which will bode very well for shareholders. And lastly, iCo’s management just issued 1.1 million options at $0.73. They haven’t issued any options for themselves since 2011, so why now? The market hopes it’s because positive news may be coming down the pipeline but no one knows for sure. "